Roswell Park Cancer Innovation SurVaxM Granted FDA Fast Track Designation
Novel cancer immunotherapy being assessed in nationwide SURVIVE trial Nationwide trials underway...
Read MoreNovel cancer immunotherapy being assessed in nationwide SURVIVE trial Nationwide trials underway...
Read MoreRoswell Park is first of several sites that will offer SurVaxM to young patients in pilot study...
Read MoreResults of phase 2A single-arm trial assessing SurVaxM plus standard therapy highlighted in poster...
Read MoreFeb 4, 2022 | All Articles, Cancer, Health | 0 |
Roswell Park Opens Phase 2B Randomized Clinical Trial of Promising Brain Cancer Immunotherapy...
Read MoreNov 20, 2019 | All Articles, Cancer, Health | 0 |
Roswell Park Spinoff Company Advances Toward New Clinical Trial for Brain Cancer Immunotherapy...
Read More